0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Editorials |

The Role of Glycemia Management in the Prevention of Cardiovascular Disease—Starting Over?

David M. Nathan, MD
[+] Article and Author Information

From Massachusetts General Hospital Diabetes Center, Boston, MA 02114.


Potential Conflicts of Interest: None disclosed.

Requests for Single Reprints: David M. Nathan, MD, Massachusetts General Hospital Diabetes Center, 50 Staniford Street, Boston, MA 02114; e-mail, dnathan@partners.org.


Ann Intern Med. 2009;151(12):888-889. doi:10.7326/0003-4819-151-12-200912150-00010
Text Size: A A A

The DCCT (Diabetes Control and Complications Trial) for type 1 diabetes (1) and the UKPDS (United Kingdom Prospective Diabetes Study) for type 2 diabetes (2) seemed to lay to rest the contentious debate over the relationship between glycemic control and the long-term complications of diabetes mellitus. These randomized trials of intensive therapy to achieve near-normal glucose control established the benefits of intensive therapy over conventional (at the time) therapy on the microvascular and neurologic complications that epidemiologic studies had shown to be associated with the level of chronic glycemia (34). Neither trial established that intensive therapy reduced cardiovascular disease (CVD), a major cause of morbidity and mortality in diabetes, possibly because of the low number of events (12, 5). Subsequent observational follow-up data demonstrated 57% and 15% reductions in major CVD events in the DCCT and UKPDS, respectively, on the basis of intention-to-treat analyses of original treatment assignment (67). The more profound effect of intensive therapy in the DCCT than in the UKPDS cohort was probably the result of greater separation in hemoglobin A1c (HbA1c) levels in the DCCT than in the UKPDS and the more complex CVD risk background of type 2 diabetes, with its associated hypertension, dyslipidemia, obesity, and older age (8). The rate of CVD was about 4-fold higher in the UKPDS population than in the DCCT population, both with about 25 years of diabetes duration (67).

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)